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1. Introduction
Melanoma is one of the most prevalent malignancies and has a very poor prognosis. Muta‐
tions in v-raf murine sarcoma viral oncogene homolog B1 (BRAF) occur in approximately
50% of melanomas [4]. While the response to selective BRAF inhibitors (BRAFi) in BRAF-
mutant melanoma is encouraging, virtually all patients rapidly develop secondary resist‐
ance [6, 7]. Based on the finding that the mitogen activated protein kinase/ERK kinase
(MEK)-extracellular signal regulated kinase (ERK) pathway is frequently reactivated by var‐
ious BRAFi resistance mechanisms, a combination trial of a selective mutant BRAF inhibitor
(dabrafenib, GSK2118436) with a MEK inhibitor (trametinib, GSK1120212) is underway and
has achieved clinical responses in 17% and disease control in 67% in patients who failed pri‐
or single-agent treatment with a BRAF inhibitor [9]. While these results are promising, there
is a critical need to overcome resistance to BRAF and MEK inhibitors. The clinical efficacy of
BRAFi and MEKi therapy is believed to rely on a functional retinoblastoma (RB) axis to in‐
hibit cell proliferation. The inhibitor of cyclin-dependent kinase 4A (INK4A) gene encode the
p16 protein, a critical cell cycle regulator that interacts with cyclin dependent kinase (CDK)
4, inhibiting its ability to phosphorylate and inactivate RB [12, 13]. Genetic disruption of
INK4A occurs in approximately 50% of melanomas irrespective of BRAF mutation and has
been detected in melanoma cells that developed resistance to BRAFi. Of note, cyclin D is still
expressed even in the setting of maximum tolerance dosing of BRAF inhibitor [7]. We have
reported that combination of BRAFi or MEKi with the expression of wild-type INK4A or a
CDK4 inhibitor (CDK4i) significantly suppresses growth and enhances apoptosis in melano‐
ma cells [1-3]. Currently, CDK4 inhibitors are in active clinical development (http://clinical‐
trials.gov/). Based on our previous work and recent insights into molecular mechanisms of
resistance to BRAF and MEK inhibitors, we hypothesize that simultaneous suppression of
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CDK4 is an effective strategy to overcome resistance to BRAF and MEK inhibitors. BRAF
mutation assays have been used to guide treatment with BRAF and MEK inhibitors, devel‐
opment of sensitive and specific INK4A/p16 assays may serve as predictive biomarkers for
treatment with CDK4 inhibitors.
2. Body
Constitutive activation of RAS-RAF-MEK-ERK signaling pathway in melanomas.NRAS
and BRAF mutations were found respectively in 10-20% and 60-80% melanomas [4]. NRAS
and BRAF are components of the RAS-RAF-mitogen activated protein kinase/ERK kinase
(MEK)-extracellular signal regulated kinase (ERK) signaling pathway (Fig. 1) [5]. This sig‐
naling pathway plays an essential role in cell proliferation, differentiation and survival [5,
14, 15]. Constitutive activation of the ERK pathway has been shown to mediate the trans‐
forming activity of mutant BRAF in melanoma cells [16-18]. Suppression of mutant BRAF
expression has been shown to inhibit ERK pathway activation and subsequent suppression
of melanoma cell proliferation and survival in vitro and in vivo [19-21]. Our previous data
revealed that the inhibition of mutant BRAF decreased levels of phospho-ERK (p-ERK), a
marker of ERK pathway activation in melanoma cells [5, 14, 15].
The high frequency of BRAF mutation in melanomas makes it an ideal target for therapy.
Because normal cells require wild-type BRAF for survival [22], specifically inhibiting mu‐
tant, but not wild-type BRAF in tumor cells could avoid toxic side effects generated by tar‐
geting normal cells. The finding that mutations in v-raf murine sarcoma viral oncogene
homolog B1 (BRAF) occur in approximately 50% of melanomas led to extensive investiga‐
tion of targeting BRAF for melanoma treatment, resulting in the first approved mutant spe‐
cific BRAF inhibitor for treatment of advanced melanoma.
Combine BRAF and MEK inhibitors with chemotherapeutic agents. Intrinsic therapy re‐
sistance is a major limitation in the treatment of malignant melanomas. The mechanisms in‐
volved in the resistance of melanomas are largely unknown [23, 24]. It is believed that
apoptosis and cytostasis (growth arrest/differentiation) are two of the main cellular respons‐
es to anticancer agents and loss of either process promotes treatment failure [25-27]. Activat‐
ing BRAF mutations could drive cell proliferation and increase the cell death threshold
through ERK pathway or alternative mechanisms [28-30], resulting in the blockage of both
cytotoxic and cytostatic effects of therapeutic drugs [14, 31, 32]. It has been shown that inhib‐
ition of ERK pathway sensitizes melanoma cells to apoptosis induced by DNA damaging
agents including cisplatin and ultra-violate (UV) irradiation [32, 33]. Rational combination of
BRAF and MEK inhibitors with selective chemotherapeutic agents, for example, dacarbazine
(DTIC), may generate additive/synergistic therapeutic effects.
ERK pathway activation and p16 in melanocytic lesions. Melanocytic lesions can be group‐
ed into two main categories: nevi and melanomas. Nevi are divided into several different
types based on histology. These include acquired melanocytic nevi, congenital melanocytic
nevi, blue nevi, Spitz nevi, and dysplastic nevi. Melanoma can be further divided based on
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clinical and traditional histological methods as superficial spreading melanoma, lentigo ma‐
ligna melanoma, acral lentiginous melanoma, and nodular melanoma. In early stages of
melanomas, neoplastic cells are confined to the epidermis or with microinvasion into the
dermis. In advanced melanomas, cancer cells expand in the dermis and generate tumor nod‐
ules and have a high potential for metastatic spread. In the metastatic phase, cancer cells dis‐
seminate to lymph nodes or distant organs [34, 35]. For the early diagnosed and localized
melanomas, surgery is the choice of treatment. But there is currently no effective treatment
for invasive and metastatic melanomas. Patients with late stage melanomas have a high
mortality rate and life expectancy averages approximately 6-8 months after diagnosis.
Figure 1. p16-cyclin D/CDK4 modifies the outcome of RAS/RAF/MEK/ERK signaling activation. RAF relays RAS signals
through MEK to ERK. The activation of this pathway has multiple effects on cell proliferation, differentiation, and sur‐
vival depending on the cellular contexts [5]. Constitutive activation of growth factor signaling pathways or NRAS and
BRAF activating mutations can trigger over-expression of p16 leading to proliferative senescence, which manifest as
benign nevus [10, 11]. Loss of p16 by genetic and epigenetic changes allows activation of cyclin D/CDK4 and inactiva‐
tion of RB, leading to E2F activation, cell cycle progression from G1 to S phase, cell proliferation and tumor formation
[12, 13]. Further genetic changes cause tumor progression to malignant melanoma. Of the three RAS and three RAF
genes, NRAS and BRAF are mutated in melanoma [4].
Of note, in addition to melanomas, BRAF mutations are found at high frequencies (70-80%)
in benign melanocytic nevi [36, 37]. There are a large numbers of melanocytic nevi in the
general population compared to the relatively low incidence of melanomas [34, 35]. Clinical‐
ly, it is known that nevi often regress over time. This suggests that BRAF mutations alone
are insufficient to induce malignant transformation in nevus cells. The growth arrest of nevi
is believed to result from oncogene-induced senescence, which is known as a protective
mechanism against unlimited proliferation that could result from BRAF mutations and acti‐
vation of the ERK signaling pathway (nevus in Fig. 1) [10, 11]. Tumor suppressor genes have
been found to be involved in senescence process. For example, p16 is one tumor suppressor
Overcoming Resistance to BRAF and MEK Inhibitors by Simultaneous Suppression of CDK4
http://dx.doi.org/10.5772/53620
5
found to be induced by ERK activation and telomere attrition involving cell senescence [8,
10, 11, 38]. The tumor suppressor p16 is encoded by INK4A (Fig. 2) and is often inactivated
in a variety of human cancers, including 30-70% in melanomas [39, 40]. Most melanomas,
but not nevi, have lost the expression of wild-type INK4A, either through DNA deletion/
mutation or promoter hypermethylation [41-45]. It is possible that the loss-of-function of p16
in melanomas may make it possible to bypass the cellular senescence mechanism and func‐
tion as an anti-tumor mechanism against ERK signal activation triggered by NRAS and
BRAF oncogenic mutation (Fig. 1) [11, 46, 47].
Indirect evidence from cultured cells and animal models reveal that there may be a coop‐
erative  role  between the  constitutive  activation of  ERK pathway and the  loss  of  p16 in
tumor progression.  Daniotti  et  al.  [48]  reported the co-existence of  BRAF  mutations and
INK4A  mutations/deletions/loss-of-expression  in  26  of  41  (63%)  short-term cell  lines  ob‐
tained from melanoma biopsies.  Recent  evidence  suggests  that  growth  arrest  in  benign
nevi is due to cell senescence and that p16 at least partially contributes to the process of
senescence in nevi [11, 46, 47].
Figure 2. INK4A and ARF share sequences in the CDKN2A locus. Exons are shown as rectangles. Alternative first exons
(1α and 1β) are transcribed from different promoters (arrows). Exons 1α and 1β are spliced to the same splicing ac‐
ceptor site in exon 2 but are translated in alternative reading frames. INK4A coding sequences in exons 1α, 2, and 3
and ARF coding sequences in exons 1β and 2 are indicated by different shading patterns. Adopted from Sherr [8].
INK4A lesions detected by FISH and Sanger sequencing may also affect ARF.
Resistance of melanoma to BRAF and MEK inhibitors. The finding that mutations in BRAF
occur in melanomas led to extensive investigation of targeting BRAF for melanoma treat‐
ment. While the response to selective mutant BRAF inhibitors (BRAFi) in BRAF-mutant mel‐
anoma is encouraging, virtually all patients rapidly develop secondary resistance. Based on
the finding that the mitogen activated protein kinase/ERK kinase (MEK)-extracellular signal
regulated kinase (ERK) pathway is frequently reactivated by various BRAFi resistance
mechanisms, the first combination trial of a selective BRAF inhibitor (dabrafenib,
GSK2118436) with a MEK inhibitor (trametinib, GSK1120212) is underway and has achieved
clinical responses in 17% and disease control in 67% in patients who failed prior single-agent
treatment with a BRAF inhibitor [9]. While these results are promising, again, the treatment
response is short-lived; there is a critical need for additional strategies to overcome this
deadly disease [49, 50].
There is evidence that treatment response to BRAFi and MEKi relies on a functional p16-
cyclin D-CDK4-retinoblastoma (RB) axis. INK4A  mutations/deletions occur in most of the
melanoma  cells  that  demonstrated  resistance  to  BRAFi  (e.g.;  451Lu,  Mel1617,  WM983,
WM902, A375, M238, SKMEL28, and A2058) [51-57]. Over-expression of cyclin D and de‐
letion  of  RB  confer  treatment  resistance  to  BRAFi  [56,  58].  Unlike  other  components  of
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the p16-cyclin D-CDK4-RB axis that harbor genetic changes at low frequency in melano‐
mas (e.g.,  CDK4  and RB  each approximately 3%) [59],  and may not overlap with BRAF
mutation  (e.g.,  amplification  of  cyclin  D1  gene  CCND1  and  CDK4)  [60],  INK4A  lesions
are  frequently  detected  in  melanomas  (~50%)  irrespective  of  BRAF  mutation  [59-61];
therefore,  abnormal  p16  is  a  major  mechanism  of  RB-axis  attenuation  in  BRAF-mutant
melanoma cells.  p16 binds to and inhibits  the catalytic  activity of  CDK4, representing a
crucial  gatekeeper at  the G1>S checkpoint  [62,  63].  The relative abundance of  CDK4-cy‐
clin D and p16 can determine the activity of the CDK4 kinase, thus regulate RB and cell-
cycle  progression  [62,  63].  BRAF-MEK-ERK signaling  pathway  upregulates/activates  the
cyclin  D-CDK4  enzyme,  which  phosphorylates  and  inactivates  RB  leading  to  cell  cycle
progression in  melanoma cells;  such an effect  can be blocked by tumor suppressor  p16
[2,  3,  61].  Several  pathways  that  confer  BRAFi  resistance,  including  COT,  RAF splicing
variants,  RAF  dimerization,  NRAS,  IGF-1R,  and  RTK  can  reactivate  cyclin  D-CDK4
through signaling pathways including MEK-ERK as well as PI3K-AKT [51-53, 55, 56, 64].
Although the addition of MEKi to BRAFi may suppress reactivation of MEK-ERK-cyclin
D-CDK4, alternative resistance mechanisms, including growth factor receptors and PI3K-
AKT pathway can activate cyclin D-CDK4 [52, 55, 64-66] in the absence of a functional p16,
adding  CDK4  inhibitor  may  help  overcoming  resistance  to  BRAFi  and  MEKi  (Fig.  3).
BRAF  mutation  assays  have  been  used  to  direct  BRAFi  treatment.  There  is  significant
genotypic heterogeneity of INK4A including bi- and mono-allelic deletions, nonsense and
missense mutations, and also different levels of epigenetic modification by promoter hy‐
per-methylation.  Characterization of  whether these INK4A  changes correlate  with differ‐
ent  treatment  resistance  to  BRAFi/MEKi/CDK4i  may lead to  companion molecular  tests
to better manage melanoma patients under BRAFi, MEKi, and CDK4i therapy.
As shown in Fig. 4, in addition to BRAF and MEK inhibitors, several drugs designed to in‐
hibit the activity of CDK4 are in active clinical trials for melanoma and other cancers includ‐




  RB-p   




Other resistant mechanisms including activation of 
growth factor receptors and PI3K-AKT 
Figure 3. The presence of functional p16 may offset resistance mechanisms that lead to activation of cyclin D-CDK4 in
melanomas that progressed under BRAFi/MEKi treatment, whereas abnormal p16 may predict treatment failure in
melanomas that develop resistance mechanisms un-opposed by BRAFi + MEKi treatment.
Combined inhibition of CDK4 potentiate the effect of MEKi. In order to design better
strategies for the treatment of this devastating disease a better understanding of melanoma
biology is necessary. Multiple genetic and environmental factors have been linked to the de‐
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velopment and aggressive behavior of melanomas [49, 50]. BRAF mutations have been iden‐
tified in approximately 60–80% of human melanomas, while NRAS mutations occur in about
10% of melanomas [4, 67]. Both NRAS and BRAF are components of the RAS-RAF-mitogen
activated protein kinase/ERK kinase (MEK)-extracellular signal regulated kinase (ERK) sig‐
naling pathway. Apart from NRAS and BRAF mutation, other factors have been identified
leading to constitutive activation of the ERK signaling, for example, amplification and so‐
matic mutations of KIT and constitutive expression of hepatocyte growth factor (HGF) and
fibroblast growth factor (FGF) [49, 50]. ERK signaling pathway controls cell proliferation,
differentiation, and survival, and has been shown to be a targetable pathway in melanoma
treatment [5, 14, 15, 68].
Deregulation of the p16-cyclin D:cyclin-dependent kinases (CDK) 4/6-retinoblastoma (RB)
pathway is a common paradigm in malignancy including melanoma [12, 13, 39] and rep‐
resents another attractive target in melanoma treatment. The great majority of melanoma
cells have lost or reduced expression of wild-type INK4A caused by genetic and epigenet‐
ic changes including mutation, deletion, and promoter hypermethylation [69, 70]. Loss of
p16 leaves cyclin D:CDK4 unoppressed to phosphorylate and inactivate RB and cell cycle
progression [8, 13, 49, 50, 69, 70]. Amplification of cyclin D1 and CDK4 genes have also
been  identified,  mostly  in  melanomas  that  harbor  wild-type  NRAS  and  BRAF  [58].  A
germ-line  Arg24Cys (R24C)  mutation in  CDK4 was identified in  familial  melanoma pa‐
tients [40, 58]. This mutation abolishes CDK4 inhibition by p16 and thus is believed to be
a  functional  equivalent  to  p16  loss.  Both  ERK  signaling  and  CDK4  kinase  have  been
shown  to  regulate  RB  protein  and  cell  cycle  progression  [58,  61].  Activation  of  BRAF-
MEK-ERK signaling pathway can cause upregulation of cyclin D resulting in the activa‐
tion of CDK4 [61]. Activated CDK4 phosphorylates and inactivated RB proteins result in
the liberation of  E2F transcription factors  and cell  cycle  progression.  It  has been shown
that  in  advanced  melanoma  cells,  RB  is  highly  phosphorylated  and  inactive,  and  E2F
transcriptional activity is constitutively high ([5, 12].
Various resistance mechanisms have been identified that contribute to treatment failure of
melanoma patients to BRAFi and MEKi therapy. Loss of p16 may represent a common gate‐
way permitting the phenotypic expression of several resistance mechanisms to BRAFi and
MEKi (Figs. 1 and 3), a hypothesis that has not been and is waiting to be tested in clinical
trials. We reported that simultaneous expression of BRAF siRNA and INK4A cDNA in mela‐
noma cells leads to dramatically increased apoptosis (17), suggesting that correcting the two
most common genetic lesions could be effective in melanoma treatment. It is unclear wheth‐
er the effect is specific to BRAF and INK4A or can be generalized to other components of the
ERK and RB pathways. It has been shown that BRAF and INK4A may have activities inde‐
pendent of the corresponding canonical ERK and RB pathways, and the two pathways also
mediate cellular signals independent of aberrant BRAF and INK4A. For example, RAF can
act through apoptosis signal-regulating kinase-1 (ASK1)/c-Jun-NH2-kinase or mammalian
sterile 20- like-kinase 2 (MST2) pathways ([71]; cyclin D:CDK4 can be activated by enhanced
phosphatidylinositol 3-kinase (PI3K) and wingless (WNT) signaling pathways in melano‐
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mas [27, 72]. Therefore, we tested PD98059 and 219476, commercially available inhibitors of
MEK and CDK4, respectively, in human melanoma cells.
Figure 4. BRAF, MEK and CDK4 inhibitors are in active clinical development and may be used in combination to in‐
crease treatment efficacy. Melanoma cells acquire resistance to BRAF and MEK inhibitors by mechanisms including ac‐
tivation of growth factor receptors and RAS signaling pathways. Activation of growth factor receptors and RAS
pathways can cause overexpression of cyclin D and activation CDK4 kinase, leading to cell cycle proliferation, which is
believed to play major roles in the emergence of treatment resistance. Adding CDK4 inhibitors may overcome resist‐
ance to treatment targeting BRAF and MEK. Apart from Vemurafenib (PLX4032, RO5185426) (Hoffmann-La Roche)
that has been U.S. Food and Drug Administration (FDA) approved for treatment of melanoma, other mutant BRAF
inhibitors including PLX3603 (RO5212054) (Hoffmann-La Roche) and GSK2118436 (dabrafenib) (GlaxoSmithKline) are
in active clinical trials. There are clinical trials of MEK inhibitors PD-325901 (Pfizer), GSK1120212 (GlaxoSmithKline),
MSC1936369B (EMD Serono), ARRY-438162 (MEK162) (Array BioPharma), AZD6244 (AstraZeneca), and BAY86-9766
(Bayer). Several drugs designed to inhibit the activity of CDK4 are also in active clinical trials for melanoma and other
cancers including PD-0332991 (Pfizer), LY2835219 (Eli Lilly and Company), LEE011 (Novartis Pharmaceuticals) (http://
clinicaltrials.gov/).
MEK inhibitor PD98059 (Calbiochem, San Diego, CA) was dissolved in dimethyl sulfoxide
(DMSO) as a 50 mM stock solution, aliquoted and stored at -20C. CDK4 inhibitor 219476
(Cat. # 219476, Calbiochem, San Diego, CA) was dissolved in DMSO as a 2 mM stock solu‐
tion and stored at 4C. Human melanoma cell lines 624Mel, A101D, and OM431 were kindly
provided by Dr. Stuart Aaronson (Mount Sinai School of Medicine, New York, NY). Cells
were maintained in Dulbecco's modified Eagle medium (DMEM) (Mediatech, Herndon, VA)
supplemented with 10% fetal bovine serum (FBS; Sigma, St. Louis, MO) and 50 units/mL
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penicillin–streptomycin (Invitrogen, Carlsbad, CA) in a humidified incubator at 37C with
5% CO2. CellTiter 96® R AQueous One Solution Cell Proliferation Assay (MTS) kit (Prome‐
ga Corporation, Madison, WI) was used to measure dehydrogenase enzyme activity found
in metabolically active cells. Melanoma cells were seeded in a 96 well plate at a density of 2
×104 cells/well in DMEM with 5% FBS. On the second day, the culture medium in each well
was changed to 150 μL DMEM without phenol red and supplemented with 0.5% FBS. Cells
were treated in triplicate for 24 and 48 hr with either vehicle solvent (control), 25 μM
PD98059, 1 μM 219476, or their combination for 624Mel; control solvent, 50 μM PD98059, 1
μM 219476, or their combination for A101D; and control solvent, 50 μM PD98059, 2 μM
219476, or their combination for OM431 cells. CellTiter 96® AQueous One Solution Reagent
(30 μL) was then added per well and cell cultures were returned to the incubator for another
4 hr. Subsequently, the absorbance of each well was measured at 450 nm with a Vmax Kinet‐
ic Microplate Reader (Molecular Devices, Sunnyvale, CA). The absorbance of the well with
only medium and CellTiter 96® AQueous One Solution Regent was background and sub‐
tracted from each sample well. The average and standard deviation of three wells with the
same treatment were calculated.
Apoptosis  was  assessed  by  terminal  deoxynucleotidyl  transferase-mediated  dUTP-biotin
nick end labeling of DNA fragments (TUNEL) method using in situ Cell Death Detection
Kit,  Fluorescein (Roche Applied Science,  Indianapolis,  IN).  Melanoma cells  were seeded
in triplicate in a 6 well plate at a density of 2 × 105 cells/well in DMEM with 5% FBS and
antibiotics.  On  the  second day,  cells  were  treated  with  PD98059  and  219476  under  the
same conditions as the MTS assay.  After  treatment with the respective chemicals  for  48
hr, cells were harvested to detect apoptotic cells using the TUNEL assay according to the
manufacturer’s  instructions (Roche Applied Science,  Indianapolis,  IN).  Using a cytospin,
cells were placed onto Polysine glass slides (Fisher Scientific, Fair lawn, NJ), fixed in 4%
paraformaldehyde  (Fisher  Scientific,  Fair  lawn,  NJ)  at  room  temperature  for  1  hr,  then
permeabilized with a fresh prepared mixture of 0.1% Triton X-100 (MP Biomedicals, Inc.
Solon, OH) and 0.1% sodium citrate (Fisher Scientific,  Fair  lawn, NJ) for 5 min at  room
temperature.  Slides were rinsed with phosphate buffered saline (PBS),  air  dried, and in‐
cubated  with  50  μL  of  TUNEL  reaction  mixture,  containing  terminal  deoxynucleotidyl
transferase (TdT)- and fluorescein isothiocyanate (FITC)-labeled dUTP, in a dark humidi‐
fied  atmosphere  at  37C  for  2  hr.  For  nuclei  counterstaining,  slides  were  cover-slipped
with  Vectashield  mounting  medium containing  DAPI  (Vector  Laboratories,  Burlingame,
CA).  Fluoresce positive cells  were viewed with a Nikon Eclipse TE 2000-U inverted mi‐
croscope (Nikon Corp., Tokyo, Japan) equipped with a FITC filter and a DAPI filter. The
percentage  of  apoptotic  cells  was  determined  for  each  sample  in  a  blind  fashion  by
counting the number of green fluorescent nuclei (TUNEL positive) among a total of 300
or more 4'-6-diamidino-2-phenylindole (DAPI)-stained blue nuclei in three random fields
at magnification of 20/0.5 (objective) as described previously [1-3].
For Western blotting, 1 × 106 melanoma cells were seeded in a cell culture dish (10 cm) in
DMEM containing 5% FBS and antibiotics. On the second day, cells were treated with
PD98059 and 219476 at the same concentration as described in the MTS assay. For cell cycle
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regulators cyclin-dependent kinase inhibitor p27 kinase interacting protein 1 (KIP1) and RB,
cells were treated with the chemicals in medium with 5% FBS for 24 hr and then harvested.
For apoptosis-related protein B-cell chronic lymphocytic leukemia (CLL)/lymphoma 2
(BCL2), BCL2-like 1 (BCL2L1 or bcl-xL), inhibitor of apoptosis family (IAP) protein baculo‐
viral IAP repeat-containing 5 (BIRC5 or survivin), apoptosis facilitator BCL2 interacting me‐
diator (BIM), cysteine-aspartic acid protease (caspase) 3, and poly (ADP-ribose) polymerase
(PARP), cells were treated with the various chemicals in DMEM with 5% FBS for 48 hr and
then harvested. For phospho- and total-ERK, cells were treated with the chemicals in medi‐
um with 0.5% FBS for 18 hr and then harvested. Western blots were performed as described
[1-3]. Briefly, harvested cells were lysed in Lysis Solution (Cell Signaling, Danvers, MA) sup‐
plemented with Complete Mini Protease Inhibitor Cocktail Tablets (Roche Diagnostics Cor‐
poration, Indianapolis, IN). Protein concentration of lysates was determined using the Quick
Start Bradford 1 × Dye Reagent (Bio-Rad, Hercules, CA). Lysates were separated in either 12
or 15% SDS-polyacrylamide gel, electrophoretically transferred to Immobilon-P membrane
(Millipore Corp, Billerica, MA), and probed with primary antibodies followed by incubation
with horseradish peroxidase-conjugated secondary antibodies. The following antibodies
were used: BCL2 and tubulin, beta (Sigma-Aldrich, St. Louis, MO); BCL2L1 and BIRC5 (San‐
ta Cruz Biotechnology, Santa Cruz, CA); phosphor-ERK, total ERK, Caspase 3, PARP, and
PhosphoPlus(R) RB (Ser780, Ser795, Ser807/811) Antibody Kit (Cell Signaling, Boston, MA);
p27KIP1 (BD Biosciences, San Jose, CA); and peroxidase-conjugated antimouse and antirab‐
bit secondary antibodies (Calbiochem, San Diego, CA). Immunoreactive bands were visual‐
ized with SuperSignal chemiluminescence substrate (Pierce, Rockford, IL). The blots were
exposed to blue sensitive blue X-ray film (Phenix Research, Candler, NC) [1-3].
Figure  5.  Regulation  of  ERK  phosphorylation,  RB  phosphorylation,  and  p27KIP1  expression  by  PD98059  and
219476,  alone and in  combination.  Human melanoma cell  lines  624Mel,  A101D,  and OM431 were treated with
either vehicle solvent (Con),  PD98059 (PD),  219476 (CD),  or  PD98059 plus 219476 (PC) as described in Materials
and methods. Western blot was performed using 20 μg total cell  lysates, tubulin was used as loading control,  as
described previously [1-3].
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Figure 6. Cytotoxicity by PD98059, 219476, and combinatorial treatment. MTS cytotoxicity assay was performed in
624Mel, A101D, and OM431 cells after (A) 24-hr and (B) 48-hr treatment in medium supplemented with 0.5% FBS.
The results are given as means ± SD from three independent tests, as described previously [1-3].
We have shown previously that human melanoma cell lines 624Mel, A101D, and OM431 cell
lines harbor heterozygous BRAF T1799A mutation and loss of wild-type INK4A [1, 61]. Cells
were treated, alone or in combination, with MEK inhibitor PD98059 (22) and CDK4 inhibitor
219476 (23). As anticipated, ERK phosphorylation was reduced in cells treated with
PD98059, and PD98059 plus 219476 (Fig. 4A). Phosphorylation of S780, S795, and S807/811 of
RB, known cyclin D:CDK4 and cyclin E:cyclin dependent kinase 2 (CDK2) targets (7),was
decreased in cells treated with either PD98059 or 219476 (except S780 and S807/811 in
OM431 cells), and further reduced in cells with combinatorial treatment (Fig. 4B). Of note,
total RB was decreased under combinatorial treatment with PD98059 and 219476 in all three
melanoma cells (Fig. 4B). Levels of p27KIP1, a negative regulator of cyclin E:CDK2, were in‐
creased in cells treated with either PD98059 or 219476, and further increased in cells with
combinatorial treatment (Fig. 4C).
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PD98059 and 219476 inhibit tumor cell growth in a dose dependent manner [1, 2]. In order
to make it possible to monitor the additional therapeutic effects of the combinatorial treat‐
ment, both chemicals were used at dosages lower than that which would lead to maximal
effect by either agent. The cytotoxicity of PD98059 and 219476 was examined 24 and 48 hr
after treatment using the MTS assay that measures the dehydrogenase enzyme activity
found in metabolically active cells. After 24-hr treatment, there was no significant difference
in cell viability between control, single, and combined treatment groups of 624Mel cells (p = .
05, R-square 0.57320, ANOVA). Small but significant differences were observed in A101D
and OM431 cells (p = .05, R-square 0.7136 and 0.8091 in A101D and OM431 cells, respective‐
ly, ANOVA); the differences were between the combined treatment vs. control and PD98059
in A101D cells, and between the combined treatment vs. control and single treatment of ei‐
ther PD98059 or 219476 in OM431 cells (Figure 2(a), HSD Test at 0.05 significance level). Af‐
ter 48-hr treatment, a significant difference in MTS counts existed for the control, PD98059,
219476, and PD98059 plus 219476 groups in all the three cell lines (p <.0001, R-square
0.981444, 0.956956, and 0.991102 in 624Mel, A101D, and OM431, respectively, ANOVA).
Further analysis showed that simultaneous treatment with PD98059 and 219476 after 48-hr
treatment resulted in significantly reduced numbers of cell survival than control-treatment
or monotreatment as measured by MTS in all the three cell lines (Fig. 6B, HSD Test at 0.05
significance level).
Next, we performed the TUNEL DNA fragmentation assay to identify loss of viability due
to programmed cell death after 48-hr treatment. As shown in Figure 3, at the drug concen‐
trations used, significantly different levels of apoptosis exist among control for PD98059,
219476, and combinatorial treatment groups (p < .0001, R-square 0.973862, 0.990697, and
0.987900 in 624Mel, A101D, and OM431, respectively, ANOVA). Treatment with PD98059
alone resulted in no difference in apoptosis over controls in all three cell lines; 219476 en‐
hanced apoptosis in OM431 but not in the other two cell lines; However, combined treat‐
ment dramatically increased apoptosis over that seen for the control-treatment and
monotreatment (Fig. 7. HSD Test at 0.05 significance level).
As apoptosis was the major effect observed when melanoma cells were exposed simultane‐
ously to MEK and CDK4 inhibitors, we examined the expression of several pro-apoptotic
and anti-apoptotic proteins. Mono-treatment with PD98059 or 219476 caused a decreased or
no change in the expression of anti-apoptotic proteins BCL2, BCL2L1, and BIRC5. While
there were variations in the patterns of expression of BCL2, BCL2L1, and BIRC5 among the
different cell lines (Fig. 8), combinatorial treatment caused a comprehensive down-regula‐
tion of the proteins in all three cell lines (Fig. 8). In addition, apoptosis facilitator BIM-EL
was increased following treatment with PD98059 and PD98059 plus 219476 in all three cell
lines. It was also increased in OM431 cells following treatment with 219476. Consistent with
increased apoptosis, caspase 3 was activated by simultaneous treatment with PD98059 plus
219476 in all three cell lines, as shown by decreased procaspase 3, increased levels of the ac‐
tive form of caspase 3 (cleaved caspase 3), and degradation of PARP, a direct substrate of
active caspase 3 (Fig. 8).
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Figure 7. MEK and CDK4 inhibitors induce apoptosis of melanoma cells.  TUNEL Assay was performed in 624Mel,
A101D and OM431 cells after 48h treatment with vehicle solvent, PD98059, 219476, or PD98059 plus 219476 in
medium with 0.5% FBS. The results were given as means ± SD from three independent assays,  as described pre‐
viously [1, 2].
 
Figure 8. Changes in the expression of pro-survival and pro-apoptotic proteins. Cells were treated with solvent vehicle
control (1), PD98059 (2), 219476 (3), and PD98059 plus 219476 (4) for 48 h in medium containing 5% FBS. Western
blotting of 20 μg total cell extracts from 624Mel, A101D and OM431 cells using BCL2, BCL2L1, BIRC5, BIM, caspase-3,
and PARP antibodies; tubulin was used as loading control, as described previously [1, 2].
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In this study, we simultaneously inhibited MEK and CDK4 kinases using pharmacological
inhibitors PD98059 and 219476 and observed significantly increased apoptosis compared to
control and single agent treatment. This is consistent with our previous report that simulta‐
neous knockdown of BRAF using small interfering RNA (siRNA) and expression of INK4A
cDNA in melanoma cells leads to a significant increase in apoptosis [1, 3]. These results
demonstrate that an increase in apoptosis can be achieved through combinatorial targeting
of ERK and RB pathways. It has been well established that constitutive activation of the ERK
signaling induces the expression of cyclin D [1, 2, 61], which binds to and activates CDK4
leading to the phosphorylation of RB protein facilitating cell cycle entry [1, 2, 61]. Consistent
with an epistatic regulation between ERK pathway and cyclin D:CDK4, amplification of cy‐
clin D1, and CDK4 genes have been identified mainly in melanomas that harbor wild-type
NRAS and BRAF [58, 60]. Additionally, cyclin D:CDK4 mediates resistance to inhibitors of
the ERK signaling pathway [58]. Therefore, the enhanced apoptosis and decreased prolifera‐
tion by simultaneously inhibiting ERK and RB pathways could result from the double hit‐
ting of ERK-cyclin D:CDK4-RB that regulate cell cycle progression and cell survival.
Alternatively, in support of our previous results that BRAF and INK4A have a nonlinear
functional interaction [1, 61], additional cellular processes could be affected when cells are
exposed to both PD98059 and 219476. ERK pathway has pleiopotent activities that regulate
cell proliferation, survival, and differentiation through both cyclin D:CDK4 dependent and
independent routes [5, 61]. Likewise, cyclin D:CDK4 can be regulated and converges multi‐
ple cellular signals. For example, while PI3K signaling can activate CDK4 through downre‐
gulation of INK4A and upregulation of cyclin D [73], WNT signaling can turn on CDK4
through suppression of INK4A transcription [72], It is conceivable that inhibition of MEK
and CDK4 not only affects ERK and RB pathways, but also PI3K, WNT, and other ERK sig‐
naling activities not mediated through the RB pathway. Therefore, simultaneous targeting of
both ERK and RB pathways can generate enhanced effects by targeting both linear and non‐
overlapping activities.
Apoptosis resistance is a critical factor for therapy failure in melanoma patients. Encourag‐
ingly, combined treatment with PD98059 and 219476 leads to significant apoptosis in all the
three melanoma cell lines studied (Fig. 7). The apoptotic rate caused by the combined treat‐
ment is higher than the combined apoptosis by monotreatment, suggesting that MEK and
CDK4 kinases mediate each other’s pro-survival effect. The apoptotic effect is associated
with changes of apoptosis-related proteins (Fig. 8). PD98059 and 219476 combined treatment
leads to significant down-regulation of the pro-survival proteins BCL2, BCL2L1, and BIRC5,
and up-regulation of the pro-apoptotic protein BIM. We showed previously that BCL2 and
BIM were regulated by BRAF and INK4A [1, 61]. BCL2L1 and BIRC5 are highly expressed in
melanoma cells, and increased expression correlates with tumor progression [74, 75]. A
straightforward explanation for the observed apoptosis is that the changes in the pro-apop‐
totic and anti-apoptotic factors offset the balance and lead to apoptosis [1]. Sequencing anal‐
ysis of TP53 cDNA [1, 3] showed that 624Mel and OM431cells respectively harbor a T1076G
(Cys275Trp) and a G1048A (Gly266Glu) mutations in the DNA binding domain that is likely
to compromise the transcription and apoptosis function of p53 [76]. No TP53 mutation has
been detected in A101D cells. Although apoptosis is enhanced in all the three cell lines, it is
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more pronounced in A101D than 624Mel and OM431 cells (Fig. 7), suggesting that TP53 sta‐
tus may influence the magnitude of apoptosis. Combinatorial-treated cells have further in‐
hibited phosphorylation of ERK and RB, reduced total RB, and increased expression of
p27KIP1 (Fig. 5). We observed similar effects on ERK and p27KIP1 in a previous report of
simultaneous expression of BRAF siRNA, and INK4A cDNA in melanoma cells [1, 3]. Yu et
al. demonstrated that loss of Rb causes apoptosis without effect on cell proliferation [77],
and Wang et al. found that overexpression of p27KIP1 leads to apoptosis in melanoma cells
[78]. The mechanisms of these changes in relationship to each other and to the observed co‐
operative effects need to be further investigated. To our knowledge, this study is the first to
demonstrate that combined inhibition of MEK and CDK4 using pharmacological inhibitors
can cooperate to trigger significant apoptosis in melanoma cells. Deregulation of the RAS-
RAF-MEK-ERK and p16-cycylin D:CDK4-RB pathways are common in human malignancies
and appears to be important for melanoma development. There has been significant effort to
target components of these pathways in cancer treatment. Pharmacologic agents targeting
components of the ERK and RB pathways have been developed. However, clinical studies
as monotherapy showed that the clinical responses have failed expectations and maximum
tolerated doses are often reached before reaching clinical efficacy. Our current study further
reinforces the notion that combination targeting of ERK and RB pathways is a promising
strategy for melanoma treatment and should encourage further in-depth investigations.
Development of biomarkers to predict treatment response to BRAF, MEK, and CDK4 in‐
hibitors. Apart from BRAF mutation, there is no other validated molecular assay to direct
BRAFi and MEKi treatment. Comprehensive and standardized INK4A molecular assays
have not been established in the context of BRAFi and MEKi treatment. Technical and clini‐
cal validation of INK4A molecular assays may lead to the clinical use of new molecular com‐
panion biomarkers to accurately predict clinical response to BRAF and MEK inhibitors, and
may also direct future combination treatment that includes CDK4 inhibitors for metastatic
melanoma. Because CDK4 is important in both normal and cancerous cells, CDK4 inhibitors
are expected to decrease the ability of the bone marrow to make white blood cells, platelets,
and red blood cells. Although these effects are expected to be reversible, they can increase
the risk of infection, bleeding and fatigue. Like BRAF inhibitors, these drugs are also expect‐
ed to be expensive. Therefore, development of predictive molecular markers, as in the case
of BRAF mutation assay for BRAFi, should help selecting patients that are likely to response
to the treatment, therefore to maximize efficacy and avoid unnecessary side-effect and treat‐
ment cost [79, 80].
Genetic and epigenetic changes of INK4A have been identified in 30-70% of melanomas irre‐
spective of BRAF mutation [59, 70, 81]. Bi-allelic deletion of INK4A (p16 null) occurs in
10-27% of melanomas [60, 82]. Other changes include mono-allelic deletion, point mutation,
or promoter hypermethylation, resulting in various levels of p16 expression/activity (Table
1) [57, 60, 81-83]. It is believed that the acquisition of p16 lesions allows melanoma cells to
bypass senescence/growth arrest during melanoma development [84]. Although preliminary
results with combination therapy of BRAFi and MEKi are encouraging with better clinical
response over single agent BRAFi treatment [9], levels of treatment responses vary under
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the combination treatment [9]. We hypothesize that clinical response to combination therapy
of BRAFi and MEKi correlates with status of INK4A/p16 (Table 2). The development of clini‐
cally useful INK4A assays requires an understanding of the underlying biology and access
to technology that allows high quality assay performance. Recent advances in molecular
technology enable accurate, rapid, and cost-effective INK4A molecular testing that can be
performed routinely on tumor specimens. However, validation of the technical performance
characteristics of INK4A assays and understanding of assay limitations are necessary for the
accurate interpretation of test results.
INK4A status p16 protein sequence and expression
Wild-type Normal sequence
Various mutations Heterogeneous sequence changes
Bi-allelic deletion Protein null
Promoter hypermethylation Lower levels of p16
Table 1. Heterogeneity of INK4A and p16 in melanoma specimens
As examples, Table 2 is a list of molecular assays to comprehensively examine INK4A/p16
lesions in melanoma specimens. Technical and clinical validation studies are necessary be‐
fore the routine use of these assays in the clinic.
Test Method Reference
INK4A deletion fluorescent in situ hybridization (FISH) (p16 SpectrumOrange/ chromosome 9
centromeric probe (CEP9) SpectrumGreen Probe, Abbott Molecular, Des
Plaines, IL)
[85, 86]
INK4A mutation Sanger sequencing [86, 87]
INK4A promoter
methylation
Pyrosequencing (PyroMark Q24 CpG p16 Kit, Qiagen, Valencia, CA) [82, 88, 89]
p16 expression Immunohistochemical staining (IHC) [90, 91]
Table 2. Summary of molecular assays
These assays need to be validated both technically and clinically with defined cut-off values.
There should be correlation of results among assay methods; for example, cells with bi-allel‐
ic INK4A deletion show negative p16 IHC staining and cells with mono-allelic INK4A dele‐
tion show mutations with loss of heterozygosity (LOH), and p16 expression inversely
correlates with levels of INK4A promoter methylation. The major obstacles in testing tumor
specimens are the presence of non-tumor cells in the samples, the cellular heterogeneity
within tumor specimens, and degradation/damage of nucleic acid and protein during sam‐
ple processing. To ensure accurate testing results, SOPs need to be established with clearly
Overcoming Resistance to BRAF and MEK Inhibitors by Simultaneous Suppression of CDK4
http://dx.doi.org/10.5772/53620
17
defined instructions on the selection and handling of tumor specimens. For example, FISH
assay requires fixation time between 6-48 hrs [92]. Alterations in INK4A may also affect the
overlapping ARF gene (Fig. 2). Although the proposed study focuses on INK4A, changes in
INK4A may also affect ARF, which may also be analyzed. Assay clinical sensitivity, clinical
specificity, positive predictive value, and negative predictive value of INK4A biomarkers for
a given treatment response can be calculated as described in Table 4.
INK4A result Treatment resistant case Treatment sensitive case
Lesion +ve A B Positive predictive value = A / (A + B)
Lesion -ve C D Negative predictive value = D / (C + D)
Sensitivity = A / (A + C) Specificity = D / (B + D)
Table 3. Calculation of clinical sensitivity, clinical specificity and predictive values
3. Conclusion
Patients with metastatic melanoma have a median survival of 6-8 months [93]. Recently, ipi‐
limumab (Yervoy, Bristol-Myers Squibb), an inhibitor of cytotoxic T-lymphocyte antigen 4
(CTLA-4) and vemurafenib (PLX4032, Zelboraf, Plexxikon/Roche), an inhibitor of mutant
BRAF, gained FDA approval to treat patients with metastatic melanoma. Although both
drugs offer new approaches to the treatment of advanced melanoma, their therapeutic effi‐
cacy is limited. Both drugs typically lengthen life by only several months in patients that ini‐
tially responded to the treatment [94, 95]. There is mounting evidence that acquired
resistance to BRAFi frequently correlates with reactivation of the RAS-RAF-MEK-ERK sig‐
naling pathway [52, 53, 64]. This finding led to clinical trials combining BRAFi and MEKi in
patients with BRAF-mutant metastatic melanoma who progressed on a prior BRAFi treat‐
ment regimen [94]. Dabrafenib (GSK2118436, GlaxoSmithKline) is a potent and selective in‐
hibitor of mutant BRAF and is comparable in safety and efficacy to vemurafenib. In phase I
testing, it achieved a 67% response rate in metastatic melanoma patients with BRAF V600
mutations [96]. Trametinib (GSK1120212, GlaxoSmithKline) is a potent and selective inhibi‐
tor of MEK1/2, achieved a clinical response of 40% in patients with an activating BRAF mu‐
tation in phase I study [97]. A multicenter phase I/II trial of combined treatment with
dabrafenib and trametinib demonstrated a disease control rate of 67% (12/18) in patients
who failed prior single-agent treatment with a BRAFi [9]. We hypothesize that although re‐
activation of MEK-ERK-cyclin D-CDK4 in tumors previously treatment with BRAFi may be
suppressed by the combination of dabrafenib and trametinib, cyclin D-CDK4 can also be re‐
activated by alternative resistance mechanisms that cannot be suppressed by the addition of
MEKi (e.g.; activation of growth factor receptor and PI3K-AKT pathway) [51-53, 55, 56, 65,
66], if unopposed by p16, can lead to resistance to the BRAFi and MEKi combination thera‐
py (Fig. 1). It has been shown that melanoma cells that harbor abnormal INK4A are more
sensitive than INK4A wild-type cells to the growth inhibitory effect of a p16-mimicking pep‐
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tide [98] or of flavopiridol, a pan-CDK inhibitor [99], and combination of BRAFi or MEKi
with the expression of wild-type INK4A or a CDK4 inhibitor significantly suppresses growth
and enhances apoptosis in melanoma cells [2, 3]. Therefore, melanoma combination treat‐
ments that include CDK4 inhibitors may overcome treatment resistance and enhance effica‐
cy. There is a critical need to identify predictive markers for therapies not only to improve
treatment outcomes, but to help avoid ineffective toxic therapies, also because of the likely
high cost of combination regimens. Like BRAF mutation assay, testing of INK4A-p16 may
predict which patients will response to BRAF, MEK, and CDK4 inhibitors. Therefore, INK4A
biomarkers may also have great potential to guide future melanoma combination treatments
that include CDK4 inhibitors.
Nomenclature
ASK1: apoptosis signal-regulating kinase-1
ARF: alternative open reading frame
BCL2: B-cell chronic lymphocytic leukemia/lymphoma 2
BCL2L1: BCL2-like 1
BIM: BCL2 interacting mediator
BIRC5: baculoviral IAP repeat-containing 5, also known as survivin
BRAF: v-raf murine sarcoma viral oncogene homolog B1
BRAFi: BRAF inhibitor
Caspase: cysteine-aspartic acid protease
CDK2: cyclin-dependent kinase 2
CDK4: cyclin-dependent kinase 4
CDK4i: CDK4 inhibitor
CEP9: chromosome 9 centromeric probe
CLL: chronic lymphocytic leukemia
DAPI: 4'-6-diamidino-2-phenylindole




FBS: fetal bovine serum
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FDA: Food and Drug Administration
FGF: fibroblast growth factor
FISH: fluorescent in situ hybridization
FITC: fluorescein isothiocyanate
HGF: hepatocyte growth factor
IAP: inhibitor of apoptosis family
IHC: immunohistochemical staining
INK4A: inhibitor of cyclin-dependent kinase 4A; part of cyclin-dependent kinase inhibitor
2A gene (CDKN2A), also known as multiple tumor suppressor 1 (MTS1)
KIP1: kinase interacting protein 1
LOH: loss of heterozygosity
MEK: mitogen-activated protein kinase/ERK kinase
MEKi: MEK inhibitor
MST2: sterile 20- like-kinase 2
PAGE: polyacrylamide gel electrophoresis
PARP: poly (ADP-ribose) polymerase
PBS: phosphate buffered saline
PI3K: phosphatidylinositol 3-kinase
p-ERK: phopho-ERK
RAF: v-raf murine sarcoma viral oncogene homolog. Human has three RAF: CRAF, BRAF,
and ARAF
RAS: rat sarcoma viral oncogene homolog. Human has three RAS: HRAS, NRAS, and KRAS
(KRAS4A and KRAS4B proteins arise from alternative splicing)
RB: retinoblastoma proteins including pRB, p107, and p103
SDS: sodium dodecyl sulfate
siRNA: small interfering RNA
TdT: terminal deoxynucleotidyl transferase
TUNEL: terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling
UV: ultra violate
WNT: wingless
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